Dukowicz AC, Lacy BE, Levine GM: Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007, 3: 112-122.
Google Scholar
Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. 1999, 116: 1461-1463. 10.1016/S0016-5085(99)70512-3.
Ghoshal UC: How to interpret hydrogen breath tests. J Neurogastroenterol Motil. 2011, 17: 312-317. 10.5056/jnm.2011.17.3.312.
Article
PubMed
PubMed Central
Google Scholar
Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003, 98: 412-419.
PubMed
Google Scholar
Jolley J: High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol. 2011, 4: 43-48. 10.2147/CEG.S18051.
Article
PubMed
PubMed Central
Google Scholar
Lombardo L, Foti M, Ruggia O, Chiecchio A: Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010, 8: 504-508. 10.1016/j.cgh.2009.12.022.
Article
PubMed
Google Scholar
Meyrat P, Safroneeva E, Schoepfer AM: Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther. 2012, 36: 1084-1093. 10.1111/apt.12087.
Article
PubMed
Google Scholar
Cuoco L, Salvagnini M: Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006, 52: 89-95.
PubMed
Google Scholar
Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW: Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci. 2007, 333: 266-270. 10.1097/MAJ.0b013e3180536784.
Article
PubMed
Google Scholar
Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A: Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol. 2009, 15: 2628-2631. 10.3748/wjg.15.2628.
Article
PubMed
PubMed Central
Google Scholar
Ford AC, Spiegel BM, Talley NJ, Moayyedi P: Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009, 7: 1279-1286. 10.1016/j.cgh.2009.06.031.
Article
PubMed
Google Scholar
Menees SB, Maneerattannaporn M, Kim HM, Chey WD: The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012, 107: 28-35. 10.1038/ajg.2011.355. quiz 36
Article
PubMed
Google Scholar
Grace E, Shaw C, Whelan K, Andreyev HJ: Review article: small intestinal bacterial overgrowth-prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013, 38: 674-688. 10.1111/apt.12456.
Article
PubMed
Google Scholar
Sperber AD, Shvartzman P, Friger M, Fich A: A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the ???true??? prevalence of irritable bowel syndrome?. Eur J Gastroenterol Hepatol. 2007, 19: 441-447. 10.1097/MEG.0b013e32801140e2.
Article
PubMed
Google Scholar
Riordan SM, McIver CJ, Walker BM, Duncombe VM, Bolin TD, Thomas MC: The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol. 1996, 91: 1795-1803.
PubMed
Google Scholar
Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, Gasbarrini G: Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis. 2007, 25: 237-240. 10.1159/000103892.
Article
PubMed
Google Scholar
Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A: Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005, 22: 1157-1160. 10.1111/j.1365-2036.2005.02690.x.
Article
PubMed
Google Scholar
Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A: Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005, 22: 31-35. 10.1111/j.1365-2036.2005.02516.x.
Article
PubMed
Google Scholar
Pimentel M: Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009, 18: 349-358. 10.1517/13543780902780175.
Article
PubMed
Google Scholar
Gillis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995, 49: 467-484. 10.2165/00003495-199549030-00009.
Article
PubMed
Google Scholar
Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011, 364: 22-32. 10.1056/NEJMoa1004409.
Article
PubMed
Google Scholar
Reischer GH, Ebdon JE, Bauer JM, Schuster N, Ahmed W, Aström J, Blanch AR, Blöschl G, Byamukama D, Coakley T, Ferguson C, Goshu G, Ko G, de Roda Husman AM, Mushi D, Poma R, Pradhan B, Rajal V, Schade MA, Sommer R, Taylor H, Toth EM, Vrajmasu V, Wuertz S, Mach RL, Farnleitner AH: Performance Characteristics of qPCR Assays Targeting Human- and Ruminant-Associated Bacteroidetes for Microbial Source Tracking across Sixteen Countries on Six Continents. Environ Sci Technol. 2013, 47: 8548-8556. 10.1021/es304367t.
Article
PubMed
PubMed Central
Google Scholar
Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundarò C, Gasbarrini A: Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013, 17: 1314-1320.
PubMed
Google Scholar
Collins BS, Lin HC: Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr. 2011, 52: 382-386. 10.1097/MPG.0b013e3181effa3b.
Article
PubMed
Google Scholar
Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F, Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F: Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. Curr Med Res Opin. 2000, 16: 14-20. 10.1185/0300799009117003.
Article
PubMed
Google Scholar
Stoicescu A, Andrei M, Becheanu G, Stoicescu M, Nicolaie T, Diculescu M: Microscopic colitis and small intestinal bacterial overgrowth-diagnosis behind the irritable bowel syndrome?. Rev Med Chir Soc Med Nat Iasi. 2012, 116: 766-772.
PubMed
Google Scholar
Chang MS, Minaya MT, Cheng J, Connor BA, Lewis SK, Green PH: Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. Dig Dis Sci. 2011, 56: 2939-2946. 10.1007/s10620-011-1719-6.
Article
PubMed
Google Scholar
Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, Gasbarrini G: Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology. 2002, 49: 1582-1586.
PubMed
Google Scholar
Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J Gastroenterol. 2005, 11: 2773-2776.
Article
PubMed
PubMed Central
Google Scholar
Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, Savarino E, Indiveri F, Savarino V, Ghio M: Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol. 2008, 103: 1257-1262. 10.1111/j.1572-0241.2007.01758.x.
Article
PubMed
Google Scholar
Furnari M, Parodi A, Gemignani L, Giannini EG, Marenco S, Savarino E, Assandri L, Fazio V, Bonfanti D, Inferrera S, Savarino V: Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2010, 32: 1000-1006. 10.1111/j.1365-2036.2010.04436.x.
Article
PubMed
Google Scholar
Rosania R, Giorgio F, Principi M, Amoruso A, Monno R, Di Leo A, Ierardi E: Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol. 2013, 8: 169-172. 10.2174/15748847113089990048.
Article
PubMed
Google Scholar
Bayeli PF, Mariottini M, Lisi L, Ferrari P, Tedone F: Linee guida sul dismicrobismo intestinale (SIBO: Small Intestinal Bacterial Overgrowth). Minerva Gastroenterol Dietol. 1999, 45: 297-308.
PubMed
Google Scholar
Yu D, Cheeseman F, Vanner S: Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011, 60: 334-340. 10.1136/gut.2009.205476.
Article
PubMed
Google Scholar